Business
COSCIENS Biopharma Inc. Reports Q1 2026 Results
TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) today reported its financial and operating results for the first quarter ended March 31, 2026. All amounts in this press release are in U.S. dollars. Q1 2026 Financial Highlights $5.0 million in cash and cash equivalents at March 31, 2026.Consolidated net income of $10.8 million or $3.42 net income per common share, as compared with a consolidated net loss of $3.7 m
About this update from Cosciens Biopharma Inc.
[{"type":"image","alt":"COSCIENS Biopharma Inc.","displaySize":"","headline":null,"caption":"COSCIENS Biopharma Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":115,"url":"https://media.zenfs.com/en/globenewswire.com/c1c23173d064dcced5831bb963ac66d2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ysOkqPWcXyAzP0v2M3xkkQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c1c23173d064dcced5831bb963ac66d2","width":300,"height":115},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ysOkqPWcXyAzP0v2M3xkkQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c1c23173d064dcced5831bb963ac66d2","width":300,"height":115}},"lazy":false},{"type":"text","content":"TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) today reported its financial and operating results for the first quarter ended March 31, 2026. All amounts in this press release are in U.S. dollars.","length":281,"tagName":"p"},{"type":"text","content":"Q1 2026 Financial Highlights","length":28,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"$5.0 million in cash and cash equivalents at March 31, 2026.","length":60,"tagName":"p"}]},{"val":[{"type":"text","content":"Consolidated net income of $10.8 million or $3.42 net income per common share, as compared with a consolidated net loss of $3.7 million, or $1.16 loss per common share for Q1 2025. The $14.4 million increase in net income is primarily attributable to the $10.9 million of Income from discontinued operations recognized upon the deconsolidation of the Company’s German subsidiaries from the consolidated financial results (as further discussed below).","length":450,"tagName":"p"}]},{"val":[{"type":"text","content":"Consolidated net loss from continuing operations of $0.2 million or $0.06 net loss per common share as compared to consolidated net loss from continuing operations of $2.7 million or $0.85 net loss per common share for Q1 2025. The $2.5 million decrease reflects a decrease in total operating expenses of $1.5 million, an increase in other income of $0.6 million, and increase in gross margin of $0.4 million.","length":409,"tagName":"p"}]},{"val":[{"type":"text","content":"Total revenue of $1.9 million a...